Merit Medical Systems Inc banner

Merit Medical Systems Inc
F:MM3

Watchlist Manager
Merit Medical Systems Inc Logo
Merit Medical Systems Inc
F:MM3
Watchlist
Price: 63 EUR -0.79% Market Closed
Market Cap: €3.7B

Wall St Price Targets

MM3 Price Targets Summary
Merit Medical Systems Inc

Wall Street analysts forecast MM3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MM3 is 93.55 EUR with a low forecast of 75.18 EUR and a high forecast of 116.18 EUR.

Lowest Forecast
Price Target
75.18 EUR
19% Upside
Average Forecast
Price Target
93.55 EUR
48% Upside
Highest Forecast
Price Target
116.18 EUR
84% Upside
Merit Medical Systems Inc Competitors:
Price Targets
ROKU
Roku Inc
9% Upside

Revenue
Forecast

11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 5 years is 7%.

Gross Profit
Forecast

11% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
11% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 5 years is 9%.

Operating Income
Forecast

15% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-43%
Average Miss
15% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-43%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 5 years is 20%.

Pre-Tax Income
Forecast

15% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-53%
Average Miss
15% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-53%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 15%. The projected CAGR for the next 3 years is 30%.

Net Income
Forecast

16% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-45%
Average Miss
16% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-45%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 16%. The projected CAGR for the next 5 years is 22%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MM3's stock price target?
Price Target
93.55 EUR

According to Wall Street analysts, the average 1-year price target for MM3 is 93.55 EUR with a low forecast of 75.18 EUR and a high forecast of 116.18 EUR.

What is the Revenue forecast for Merit Medical Systems Inc?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 5 years is 7%.

What is the Gross Profit forecast for Merit Medical Systems Inc?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 5 years is 9%.

What is the Operating Income forecast for Merit Medical Systems Inc?
Projected CAGR
20%

Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 5 years is 20%.

What is the Pre-Tax Income forecast for Merit Medical Systems Inc?
Projected CAGR
30%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 15%. The projected CAGR for the next 3 years is 30%.

What is the Net Income forecast for Merit Medical Systems Inc?
Projected CAGR
22%

Over the last 13 years, the compound annual growth rate for Net Income has been 16%. The projected CAGR for the next 5 years is 22%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett